New perspectives on molecular targeted therapy in ovarian clear cell carcinoma

Area of Science:

• Gynecologic Oncology
• Molecular Pathology
• Translational Medicine

Background:

• Ovarian clear cell carcinomas (OCCCs) represent 5-13% of epithelial ovarian cancers in Western countries.
• OCCCs exhibit significant resistance to standard platinum-based chemotherapy, highlighting an unmet clinical need.
• Understanding the molecular drivers of OCCC is crucial for developing effective therapeutic strategies.

Purpose of the Study:

• To review recent advancements in understanding the molecular pathogenesis of OCCC.
• To identify novel therapeutic targets and opportunities based on molecular discoveries.
• To provide an overview of emerging treatment strategies for OCCC.

Main Methods:

• Literature review of recent research on OCCC molecular biology.
• Analysis of key genetic mutations and signaling pathway alterations in OCCC.
• Identification of potential therapeutic targets including ARID1A, PI3K/AKT pathway, and angiogenesis.

Main Results:

• Mutations in ARID1A are frequently observed in OCCC and linked to endometriosis.
• Upregulation of the phosphatidylinositol 3-kinase/AKT pathway, via PIK3CA mutations and PTEN inactivation, is a key feature.
• Increased angiogenesis and potential for targeting HER2, apoptosis, and mismatch repair defects were identified.

Conclusions:

• Recent molecular discoveries have significantly improved our understanding of OCCC pathogenesis.
• Targeting specific molecular alterations like ARID1A, PI3K/AKT pathway, and angiogenesis offers promising therapeutic avenues.
• Exploiting HER2, apoptotic escape, and mismatch repair defects presents additional opportunities for OCCC treatment.